New shot tested to slow kidney disease in IgA nephropathy patients

NCT ID NCT07305974

Summary

This study is testing an investigational injection called RG002C0106 for adults with IgA nephropathy, a kidney disease. It aims to see if the treatment safely reduces protein in the urine and helps protect kidney function over 24 weeks. The trial will involve about 30 participants who will receive either the real injection or a placebo, with neither they nor their doctors knowing which one.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University First Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.